http://www.law360.com/ Latest articles for organization: H Lundbeck Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/132727 Infosint SA has asked a judge to increase a $15 million reasonable royalty award that a jury issued for Lundbeck A/S and Forest Laboratories Inc.'s alleged infringement of a patent for making the antidepressant citalopram, arguing that it should receive additional damages and interest totaling almost $43 million. http://www.law360.com/articles/132727 http://www.law360.com/articles/128894 Lundbeck A/S and Forest Laboratories Inc. will have to pay Infosint SA a $15 million reasonable royalty award now that a federal jury has ruled that Infosint's patent for making the antidepressant citalopram is valid. http://www.law360.com/articles/128894 http://www.law360.com/articles/128638 A federal judge has refused to dismiss a putative class action accusing Ovation Pharmaceuticals Inc. and Lundbeck Inc. of jacking up the prices for pharmaceutical treatments of a certain congenital heart defect suffered most frequently by premature infants. http://www.law360.com/articles/128638 http://www.law360.com/articles/110772 Sun Pharmaceutical Industries Ltd. has reached a deal with Forest Laboratories Inc. to license several patents related to the antidepressant Lexapro, bringing an end to a long-running patent suit between the drugmakers. http://www.law360.com/articles/110772 http://www.law360.com/articles/109269 A federal judge has rejected the latest bid from H. Lundbeck A/S and its partner Forest Laboratories Inc. to pare down a patent dispute related to the antidepressant citalopram, ruling that a lone letter from one of the companies' suppliers did not yield enough evidence to drop part of Infosint SA's infringement claims. http://www.law360.com/articles/109269 http://www.law360.com/articles/104019 In a blow to both sides battling over conflicting patents related to the antidepressant citalopram, a federal judge has found two claims of plaintiff Infosint SA's patent obvious but also invalidated the first claim of defendant H. Lundbeck A/S' patent after finding the company had suppressed or concealed its invention. http://www.law360.com/articles/104019 http://www.law360.com/articles/100317 In a patent infringement suit brought by Infosint SA over the antidepressant citalopram, a federal judge has refused to limit Forest Laboratories Inc.'s liability through a law meant to protect "innocent infringers" before they know about a patent. http://www.law360.com/articles/100317 http://www.law360.com/articles/95521 Officials at the U.S. Food and Drug Administration have expressed concern about a risk of cardiac arrhythmia and death associated with Danish drugmaker H. Lundbeck A/S's proposed schizophrenia drug Serdolect. http://www.law360.com/articles/95521 http://www.law360.com/articles/88514 In refusing to hear an appeal from Forest Laboratories Inc. on Monday, the U.S. Supreme Court has allowed Caraco Pharmaceutical Laboratories Ltd. to continue its bid to invalidate a patent for antidepressant Lexapro despite Forest's earlier covenant not to sue the generics manufacturer over the patent. http://www.law360.com/articles/88514 http://www.law360.com/articles/85297 A federal district judge has rejected Forest Laboratories Inc.'s second bid to toss one of Caraco Pharmaceutical Laboratories Ltd.'s declaratory actions against the company over a patent for the depression treatment Lexapro. http://www.law360.com/articles/85297 http://www.law360.com/articles/84696 Caraco Pharmaceutical Laboratories Ltd. has filed a new declaratory action against Forest Laboratories Inc. over a third patent for Lexapro in the generics manufacturer's latest bid to market its own version of the depression treatment. http://www.law360.com/articles/84696 http://www.law360.com/articles/52762 A British appellate court has overturned a ruling that found claims in H. Lundbeck A/S’ patent for its antidepressant drug Cipralex insufficient, scoring a win for the Danish pharmaceutical company in an ongoing patent challenge brought by three generics makers. http://www.law360.com/articles/52762 http://www.law360.com/articles/34084 A federal appeals court panel has upheld both the validity of Forest Laboratories Inc.’s patent on the blockbuster antidepressant drug Lexapro and an injunction thwarting Ivax Pharmaceuticals Corp.’s plans to market a generic. http://www.law360.com/articles/34084 http://www.law360.com/articles/24135 Danish pharmaceutical company H. Lundbeck A/S suffered a blow Friday when a British court ruled against it in a patent dispute with three generic makers over a patent for its top-selling antidepressant drug, Cipralex. http://www.law360.com/articles/24135 http://www.law360.com/articles/19052 In an attempt to horn in on the lucrative market for depression drug Lexapro, Caraco Pharmaceutical Laboratories Ltd. has filed a lawsuit looking to force a court ruling on a patent licensed to Forest Laboratories Holdings Ltd. http://www.law360.com/articles/19052 http://www.law360.com/articles/7513 A federal judge has upheld Forest Laboratories Inc.’s patent on the blockbuster antidepressant drug Lexapro, thus thwarting Ivax Pharmaceuticals Corp.’s plans to market a generic. http://www.law360.com/articles/7513 http://www.law360.com/articles/7434 Forest Laboratories Inc. and its Danish licensing partner H. Lundbeck A/S have filed their third separate lawsuit to stop a generic version of the blockbuster antidepressant drug Lexapro from entering the market. http://www.law360.com/articles/7434 http://www.law360.com/articles/7088 Leading IP law firm Darby & Darby has expanded its operations overseas to Frankfurt, Germany, where it will offer U.S. IP law services to European clients. http://www.law360.com/articles/7088 http://www.law360.com/articles/5771 Firing the opening shot at trial, generic drug maker Ivax Corp. vigorously defended its alleged infringement of the antidepressant Lexapro, asserting that Forest Laboratories’ patent for the blockbuster drug is invalid. http://www.law360.com/articles/5771 http://www.law360.com/articles/4203 Generic drug maker Alphapharm Pty Ltd. must steer clear of blockbuster antidepressant Lexapro for now as part its settlement agreement with Forest Laboratories Inc., ending litigation launched in May 2004. http://www.law360.com/articles/4203